A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo

International Journal of Cancer

Volumn 131, Issue 10, 2012, Pages 2411-2419

  Ling, Chunhua ^a   Chen, Gang ^a   Chen, Guodong ^a   Zhang, Zubin ^a   Cao, Biyin ^a   Han, Kunkun ^a   Yin, Jianming ^b   Chu, Alex ^b   Zhao, Yun ^a   Mao, Xinliang ^a  

^a SOOCHOW UNIVERSITY   (China)

^b Borui Pharmaceutics Inc   (China)

Author keywords

cell cycle; dasatinib; deuterium substitution; non small cell lung cancer

Indexed keywords

BRP 800; BRP 801; BRP 802; BRP 803; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN A; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; DASATINIB; DEUTERIUM; DOCETAXEL; N [(2 CHLORO 6 METHYL PHENYL) 2 (6 CHLORO 2 METHYL PYRIMIDIN 4 YL)AMINO]THIAZOLE 5 CARBOXAMIDE; OCTADUTERIOPIPERAZINE DIHYDROCHLORIDE; PROTEIN BCL 2; PROTEIN KINASE P60; PROTEIN MCL 1; PROTEIN P21; PROTEIN P27; PROTEIN P53; TERT BUTYL 2,2,3,3,5,5,6,6 OCTADUTERIOPIPERAZINE 1 CARBOXYLATE; TERT BUYTL 4 [6 [[5 [(2 CHLORO 6 METHYL PHENYL)CARBOMYL]THIAZOL 2 YL]AMINO] 2 METHYL PYRIMIDIN 4 YL] 2,2,3,3,5,5,6,6 OCTADEUTERIOPIPERAZINE 1 CARBOXYLATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DEVELOPMENT; ENZYME ACTIVATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DEUTERIUM; ENZYME ACTIVATION; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; PYRIMIDINES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THIAZOLES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867062548     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27504     Document Type: Article

References (31)

1. Cancer Facts and Figures 2008. American Cancer Society, 2008: 9-14.
2. Thun MJ, Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, Feskanich D, Flanders WD, Jee SH, Katanoda K, Kolonel LN, Lee IM, Marugame T, et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 2008; 5: e185.
3. Wheeler DL, Dunn EF, Harari PM,. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7: 493-507.
4. Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, Li JQ, Yoneyama H, Uchida N, Fujita J, Yoshiji H, Watanabe S, et al. pp60c-src activation in lung adenocarcinoma. Eur J Cancer 2003; 39: 1447-55.
5. Calalb MB, Polte TR, Hanks SK,. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 1995; 15: 954-63.
6. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB,. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 2003; 278: 40057-66.
7. Cao X, Tay A, Guy GR, Tan YH,. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell Biol 1996; 16: 1595-603.
8. Irby RB, Yeatman TJ,. Role of Src expression and activation in human cancer. Oncogene 2000; 19: 5636-42.
9. Roskoski R, Jr,. Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 2004; 324: 1155-64.
10. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 2010; 6: 291-9.
11. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, Lee F, Shaw P, Clark E,. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007; 67: 2226-38.
12. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1387-94.
13. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ,. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 4609-15.
14. Kushner DJ, Baker A, Dunstall TG,. Pharmacological uses and perspectives of heavy water and deuterated compounds. Can J Physiol Pharmacol 1999; 77: 79-88.
15. Kerekes AD, Esposite SJ, Doll RJ, Tagat JR, Yu T, Xiao Y, Zhang Y, Prelusky DB, Tevar S, Gray K, Terracina GA, Lee S, et al. Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure. J Med Chem 2011; 54: 201-10.
16. Clarke KO, Ludeman SM, Springer JB, Colvin OM, Lea MA, Harrison LE,. Exposure to a deuterated analogue of phenylbutyrate retards S-phase progression in HT-29 colon cancer cells. J Pharm Sci 2002; 91: 1054-64.
17. Mao X, Hou T, Cao B, Wang W, Li Z, Chen S, Fei M, Hurren R, Gronda M, Wu D, Trudel S, Schimmer AD,. The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence. Mol Pharmacol 2011; 79: 672-80.
18. Mao X, Cao B, Wood TE, Hurren R, Tong J, Wang X, Wang W, Li J, Jin Y, Sun W, Spagnuolo PA, MacLean N, et al. A small-molecule inhibitor of D -cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood 2011; 117: 1986-97.
19. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB,. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006; 66: 5542-8.
20. Johnson FM, Saigal B, Talpaz M, Donato NJ,. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005; 11: 6924-32.
21. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13: 3989-98.
22. Sampath D, Discafani CM, Loganzo F, Beyer C, Liu H, Tan X, Musto S, Annable T, Gallagher P, Rios C, Greenberger LM,. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Ther 2003; 2: 873-84.
23. Vanhoefer U, Cao S, Harstrick A, Seeber S, Rustum YM,. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann Oncol 1997; 8: 1221-8.
24. Shao L, Abolin C, Hewitt MC, Koch P, Varney M,. Derivatives of tramadol for increased duration of effect. Bioorg Med Chem Lett 2006; 16: 691-4.
25. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S,. The protein kinase complement of the human genome. Science 2002; 298: 1912-34.
26. Thomas SM, Brugge JS,. Cellular functions regulated by Src family kinases. Ann Rev Cell Dev Biol 1997; 13: 513-609.
27. Frame MC, Fincham VJ, Carragher NO, Wyke JA,. v-Src's hold over actin and cell adhesions. Nat Rev Mol Cell Biol 2002; 3: 233-45.
28. Brown L, Boswell S, Raj L, Lee SW,. Transcriptional targets of p53 that regulate cellular proliferation. Crit Rev Eukaryot Gene Expr 2007; 17: 73-85.
29. Amaral JD, Xavier JM, Steer CJ, Rodrigues CM,. The role of p53 in apoptosis. Discov Med 2010; 9: 145-52.
30. Marcotte R, Smith HW, Sanguin-Gendreau V, McDonough RV, Muller WJ,. Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis. Proc Natl Acad Sci USA 2012; 109: 2808-13.
31. Park EJ, Min HY, Chung HJ, Hong JY, Kang YJ, Hung TM, Youn UJ, Kim YS, Bae K, Kang SS, Lee SK,. Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. Cancer Lett 2009; 277: 133-40.